Condition (MeSH)
Epilepsy, Benign Neonatal
ClinicalTrials.gov lists 1 trial for Epilepsy, Benign Neonatal or a narrower condition beneath it. NEMA Research, Inc. has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
3 sections measured, none recorded · 1 not measured yet · 1 not computed
1 of the 1 trial is tagged with Epilepsy, Benign Neonatal itself; the rest are tagged with a narrower condition beneath it.
When did Epilepsy, Benign Neonatal trials start? (1)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2021 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 1 trial evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Epilepsy, Benign Neonatal trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Phase 3 | 1 |
How many Epilepsy, Benign Neonatal trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Terminated | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Epilepsy, Benign Neonatal trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| NEMA Research, Inc. | 1 |
Which serious adverse events do Epilepsy, Benign Neonatal trials report? (1)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| pulmonary hypertension | 1 | 1 |
Which publications cover Epilepsy, Benign Neonatal? (9)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The ILAE classification of seizures and the epilepsies: Modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures. | Epilepsia | 2021 | Yes |
| Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial. | Pediatrics | 2020 | Yes |
| PRRT2 mutations: a major cause of paroxysmal kinesigenic dyskinesia in the European population. | Neurology | 2012 | Yes |
| Bumetanide enhances phenobarbital efficacy in a neonatal seizure model. | Annals of neurology | 2008 | Yes |
| Gaussian process modeling of EEG for the detection of neonatal seizures. | IEEE transactions on bio-medical engineering | 2007 | Yes |
Showing 5 of 9 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.